Miller K - Search Results

1

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.

Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE. Wardley A, et al. Among authors: miller k. Breast Cancer Res Treat. 2021 May;187(1):155-165. doi: 10.1007/s10549-021-06109-7. Epub 2021 Feb 16. Breast Cancer Res Treat. 2021. PMID: 33591468 Free PMC article. Clinical Trial.

2

Taxanes in the treatment of breast cancer: a prodigy comes of age.

Miller KD, Sledge GW Jr. Miller KD, et al. Cancer Invest. 1999;17(2):121-36. Cancer Invest. 1999. PMID: 10071597 Review.

3

Metastatic breast cancer: the role of chemotherapy.

Sledge GW Jr, Miller KD. Sledge GW Jr, et al. Among authors: miller kd. Semin Oncol. 1999 Feb;26(1 Suppl 2):6-10. Semin Oncol. 1999. PMID: 10190779 Review.

4

The role of chemotherapy for metastatic breast cancer.

Miller KD, Sledge GW Jr. Miller KD, et al. Hematol Oncol Clin North Am. 1999 Apr;13(2):415-34. doi: 10.1016/s0889-8588(05)70063-0. Hematol Oncol Clin North Am. 1999. PMID: 10363138 Review.

5

Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.

Miller KD, Sisk J, Ansari R, Gize G, Nattam S, Pennington K, Monaco F, Sledge GW Jr. Miller KD, et al. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):38-40. Oncology (Williston Park). 2001. PMID: 11252888 Clinical Trial.

6

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.

Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. Miller KD, et al. Clin Cancer Res. 2004 Mar 15;10(6):1971-5. doi: 10.1158/1078-0432.ccr-03-0968. Clin Cancer Res. 2004. PMID: 15041714 Clinical Trial.

7

Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?

Miller KD. Miller KD. Breast Cancer Res. 2004;6(3):128-32. doi: 10.1186/bcr782. Epub 2004 Mar 18. Breast Cancer Res. 2004. PMID: 15084233 Free PMC article. Review.

8

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Miller KD, et al. J Clin Oncol. 2005 Feb 1;23(4):792-9. doi: 10.1200/JCO.2005.05.098. J Clin Oncol. 2005. PMID: 15681523 Clinical Trial.

9

Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.

Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, Badve S, Storniolo A, Goulet R, Sledge GW Jr. Miller KD, et al. Breast Cancer Res Treat. 2005 Jan;89(2):187-97. doi: 10.1007/s10549-004-2044-y. Breast Cancer Res Treat. 2005. PMID: 15692762 Clinical Trial.

10

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.

Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. Miller KD, et al. Clin Cancer Res. 2005 May 1;11(9):3369-76. doi: 10.1158/1078-0432.CCR-04-1923. Clin Cancer Res. 2005. PMID: 15867237 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,558 results

Search Page